Biotalys has obtained patents for its first biofungicide, EVOCA, from both the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO).

According to Kevin Helash, chief executive officer of Biotalys, these decisions “confirm the truly innovative nature of our solution and provide Biotalys with the exclusivity needed to support our commercial partners in producing or distributing EVOCA across Europe and the United States. This will ultimately benefit fruit and vegetable growers seeking to protect their crops against certain fungal diseases.”

In addition, Biotalys has requested patent protection for the product’s active ingredient in countries around the globe, such as Argentina, Brazil and South Africa. The company has already obtained various patents worldwide on different elements of its technology and is continuously building its intellectual property protection for its products, formulations and processes.

EVOCA is a novel protein-based biofungicide that earned an entirely new resistance classification by the Fungicide Resistance Action Committee (FRAC). The product helps control fungal disease in fruits and vegetables.

EVOCA is currently under review by the U.S. Environmental Protection Agency (EPA) and the Dutch College voor Toelating van Gewasbeschermingsmiddelen en Biociden (CTGB) in the European Union for regulatory approval.

EVOCA will pave the way for EVOCA NG, which is expected to be Biotalys’ first commercial fungicide from its AGROBODY technology platform. EVOCA and EVOCA NG have the same active ingredient which is now protected by the patent grants in Europe and the US.

READ MORE ABOUT BIOTALYS’ EVOCA